SAN DIEGO — Two proposed new multiple myeloma staging systems offer similar prognostic accuracy compared with the standard staging system, but the new systems provide more refined risk classifications ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health issues. The high relapse rates following initial treatments make the search for ...

Using nationwide electronic health record (EHR) and cancer registry data from the VA Corporate Data Warehouse, we developed and validated a rule-based NLP algorithm to extract oncologist-determined MM ...

The stage of diagnosis can impact survival rates. Patients with stage III multiple myeloma (MM) have an average life expectancy of 29 months, whereas patients with stages I and II disease survive on ...

Staging, the process of finding out how advanced the cancer is, is very important because the treatment options and the outlook for recovery and survival depend on the stage of the cancer. Knowing all ...

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder. J ...

Pfizer reported that its multiple myeloma therapy Elrexfio met the primary goal in a late-stage study, significantly extending progression-free survival for patients who had received at least one ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Sarah ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...

Pfizer’s multiple myeloma drug Elrexfio met its main goal in a late-stage trial, delivering a statistically significant and clinically meaningful improvement in progression-free survival over standard ...